Overview
EYPT market data
Price History
EYPT price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for EYPT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — EyePoint, Inc. (EYPT)SEC EDGAR · Jul 17, 2026, 8:05 PM
EyePoint Pharmaceuticals To Pay $4.6M to Resolve False Claims Act AllegationsBenzinga · Jul 17, 2026, 2:22 PM
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jul 16, 2026, 11:46 AM
Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40Benzinga · Jul 16, 2026, 9:48 AM
Cantor Fitzgerald Assumes EyePoint at Overweight, Announces Price Target of $47Benzinga · Jul 8, 2026, 1:15 PM
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65Benzinga · Jul 1, 2026, 1:00 PM
Guggenheim Reiterates Buy on EyePoint, Maintains $68 Price TargetBenzinga · Jun 24, 2026, 2:00 PM
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Globenewswire Inc · Jun 16, 2026, 11:15 AM
EyePoint Announces Participation at Upcoming Investor ConferencesGlobenewswire Inc · May 19, 2026, 11:15 AM
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsGlobenewswire Inc · May 6, 2026, 11:05 AM